CDNF

Drug Name: CDNF
Company: Herantis
Location: Finland
Website: http://www.herantis.com/
Drug Type: Protein Biologic
Conditions: ALS, Parkinson’s disease
Mechanism Type: Neuroprotection
Mechanism: Enhancing trophic support from neurotrophic factors is beneficial in ALS mouse models. In preliminary unpublished studies, a single dose of one of these substances, cerebral dopamine neurotrophic factor (CDNF), improved survival in ALS mouse models. In non-human primate studies, CDNF has shown neuroprotective and regenerative capacity for dopamine-generating cells. Signs of efficacy are also seen in non-motor symptoms based on preclinical studies.
U.S. Status for ALS: Preclinical

References:
[1] Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease. ClinicalTrials.gov, 4 Oct 2017. Accessed 8 Feb 2018 from https://clinicaltrials.gov/ct2/show/NCT03295786/.
[2] Herantis Pharma Plc. HORN International, n.d. Accessed 9 Mar 2016 from http://hornonline.com/herantis-pharma-plc/.
[3] Novel CDNF/MANF Family of Neurotrophic Factors. Lindholm P, Saarma M. Dev Neurobiol. 2010 Apr;70(5):360-71.
[4] Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson’s Disease. Garea-Rodriguez, E et al. PLoS One. 2016 Feb 22;11(2):e0149776.

Last updated February 3rd, 2016

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail